By Brian Kennedy, Executive Director of the Global Alliance for Patient Access When should patients switch from one medicine to another for non-medical reasons? How can
“Doctor, make my pain go away.” I hear this plea, in one form or another, from patients on a daily basis. Yet it presents physicians like
What can the federal government do to raise clinical trials awareness? Maybe a lot, suggests one organization. May 1-5 marks Clinical Trials Awareness Week, when
Rejection is never pleasant. But for the 34,459 patients whose health plans refuse to cover advanced treatment for high cholesterol, it could also be deadly.
Promising clinical trials data has excited patients with cystic fibrosis and their families. But will access barriers dash their hopes for more and better treatment
What is good value in terms of cancer treatment? The question, amid rising cancer care costs, has prompted a surge of oncology value models in
Physicians and patients are no longer asking if a biological medicine is the best choice, but – more likely – which biological medicine is the
First came biologics, then biosimilars. And soon, explains a newly released video from The Alliance for Patient Access, patients can expect interchangeable biosimilars. According to